By Deena Beasley SAN DIEGO, June 22 (Reuters) - China, which now conducts more clinical drug trials than the U.S., still lags ...

In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the State Street SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched ...

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...

U.S. drug companies are accelerating licensing deals with Chinese pharmaceutical companies to take advantage of China’s ...

The total funding comprises US$1 million in angel investment and a US$4 million seed round. The seed financing round was led by Wavemaker Ventures, with participation by SEEDS, further supported by ...

A bill before Congress would amend the COINS Act, which restricts American investment in sensitive technologies abroad, to ...

Sacramento’s permanent R&D tax credit cap puts biomedical innovation at risk. Read the urgent 2026 sector report to protect ...

Danaher is seeing strong Biotechnology growth as bioprocessing demand rises, with equipment orders up more than 30% and core ...

The investment seeks to track the investment results of the NYSE Biotechnology Index composed of U.S.-listed equities in the ...

BENGALURU: Karnataka’s biotechnology ecosystem received a glimpse of the state’s future roadmap as the 64th meeting of the ...